Publications

Register to Read

2007
Book

Perspectives on Risk and Regulation: The FDA at 100

By: Arthur A. Daemmrich and Joanna Radin

Perspectives on Risk and Regulation: The FDA at 100 brings together the viewpoints of Food and Drug Administration officials and industry leaders on the future of regulating food, drugs, medical devices, and dietary supplements. In a period of rapid scientific... View Details

Keywords: Private Sector; Governing Rules, Regulations, and Reforms; Policy; Health Care and Treatment; Business and Government Relations; Risk and Uncertainty; Cooperation

August 2018
Article

The Impact of the Entry of Biosimilars: Evidence from Europe

By: Fiona M. Scott Morton, Ariel Dora Stern and Scott Stern

Biologics represent a substantial and growing share of the U.S. drug market. Traditional “small molecule” generics quickly erode the price and share of the branded product upon entry; however, only a few biosimilars have been approved in the U.S. since 2015, thereby... View Details

Keywords: Health Care; Biosimilars; Biologics; Pharmaceutical Competition; Healthcare Spending; Innovation; Health Care and Treatment; Spending; Market Entry and Exit; Competition; Innovation and Invention; Pharmaceutical Industry; United States; Europe

Register to Read

January 2008 (Revised January 2008)
Case

Two Brattle Center: A Mental-Health Clinic in Search of a Viable Operating Model

By: Robert G. Eccles

Two Brattle Center (TBC) is a struggling for-profit private mental health clinic based in Harvard Square. Its founder, Dr. Joan Wheelis, is a nationally recognized practicing psychiatrist who has developed outpatient treatment programs based on Dialectical Behavior... View Details

Keywords: Business Model; For-Profit Firms; Decision Choices and Conditions; Financial Strategy; Health Care and Treatment; Health Disorders; Medical Specialties; Nonprofit Organizations; Emotions; Health Industry; United States

Educators

Purchase

October 2020 (Revised November 2023)
Case

COVID-19 Testing at Everlywell

By: Jeffrey J. Bussgang and Olivia Hull

In March 2020, as COVID-19 spreads rapidly across the U.S., Everlywell founder Julia Cheek considers how to respond as a small start-up specializing in at-home lab testing. After making dramatic budget cuts, she decides to pivot the organization to address the... View Details

Educators

Purchase

26 Apr 2023
Cold Call Podcast

How Martine Rothblatt Started a Company to Save Her Daughter

Keywords: Re: Debora L. Spar; Pharmaceutical; Medical Devices & Supplies; Health

Article

Overturning the ACA's Medicaid Expansion Would Likely Decrease Low-Income, Reproductive-Age Women's Healthcare Spending and Utilization

By: Lucy Chen, Richard G. Frank and Haiden A. Huskamp

In late 2020, the Supreme Court began hearing a case challenging the Affordable Care Act (ACA), which led to coverage gains for many low-income, reproductive-age women. To explore potential implications of a full ACA repeal for this population, we examined gains... View Details

Keywords: Medicaid; Women's Health; Health Insurance; Health Care and Treatment; Gender; Insurance; Poverty; Health Industry; United States

2020
Working Paper

What Can Economics Say About Alzheimer's Disease?

By: Amitabh Chandra, Courtney Coile and Corina Mommaerts

Alzheimer’s Disease (AD) affects one in ten people aged 65 or older and is the most expensive disease in the United States. We describe the central economic questions raised by AD. While there is overlap with the economics of aging, the defining features of the... View Details

Keywords: Health Disorders; Health Care and Treatment; Economics

September–October 2020
Article

The Past, Present, and (Near) Future of Gene Therapy and Gene Editing

By: Julia Pian, Amitabh Chandra and Ariel Dora Stern

Emerging gene therapy and gene-editing technologies will have a growing impact on patient lives and health-care delivery. We analyzed a decade of data on clinical trials and venture capital investments to understand the likely trajectory of genetically focused... View Details

Keywords: Gene Therapy; Gene Editing; Impact; Health Care and Treatment; Technological Innovation; Health Testing and Trials; Venture Capital; Change

January 2021
Case

Value-Based Insurance Design at Onex

By: Joshua Schwartzstein, Amitabh Chandra and Amram Migdal

The operating executives of Health and Benefits for Onex Partners, Megan Jackson Frye and Sam Camens, faced a challenge: Healthcare costs for employees of Onex’s portfolio companies were continuing to rise above the consumer price index, reflecting broader trends... View Details

Educators

Purchase

15 Apr 2014
First Look

First Look: April 15

Purchase this case: http://hbr.org/product/pepsico-profits-and-food-the-belt-tightens/an/314055-PDF-ENG Harvard Business School Case 313-012 Cancer Treatment Centers of America® (A) Cancer Treatment Centers... View Details

Keywords: Sean Silverthorne

2024
Article

Effects of a Real-Time Information-Based Intervention on Physician Prescribing Behavior

By: Olivia Zhao and Anna D Sinaiko

High out-of-pocket (OOP) prices for prescription drugs create financial difficulties for patients, and cost-related underuse of medications can adversely patient health. Simultaneously, many physicians report a willingness to address affordability concerns with... View Details

Keywords: Price; Health Care and Treatment; Communication Technology; Technology Adoption; Customer Focus and Relationships; Health Industry

Register to Read

2015
Working Paper

Blinded by Experience: Prior Experience, Negative News and Belief Updating

By: Bradley R. Staats, Diwas S. KC and Francesca Gino

Traditional models of operations management involve dynamic decision-making assuming optimal (Bayesian) updating. However, behavioral theory suggests that individuals exhibit bias in their beliefs and decisions. We conduct both a field study and two laboratory studies... View Details

Keywords: Behavioral Operations; Egocentric Bias; Experience; Healthcare Operations; Prejudice and Bias; Behavior; Operations; Decision Making; Health Care and Treatment

SSRN

02 Mar 2007
What Do You Think?

What Is the Government’s Role in US Health Care?

Newman), the high cost of new technology, artificial restrictions on the supply of drugs (Sergey Mirkiin) and healthcare providers (David Stahl and Michael Robbins), the size and complexity of the problem itself (James Sullivan),... View Details

Keywords: by Jim Heskett; Health

05 Dec 2017
First Look

First Look at New Research and Ideas, December 5, 2017

scientific collaborators. We generated exogenous variation in search costs for pairs of potential collaborators by randomly assigning individuals to 90-minute structured information-sharing sessions as part of a grant funding opportunity. We estimate that the View Details

Keywords: Sean Silverthorne

25 Jul 2023
Research & Ideas

Could a Business Model Help Big Pharma Save Lives and Profit?

With Hepatitis C running rampant in Egypt in 2012, Clifford Samuel, then of California-based Gilead Sciences, convened a series of urgent meetings with Egyptian government officials, doctors, and patients. His goal? To make Gilead’s lifesaving Hepatitis C View Details

Keywords: by Esther Schrader; Pharmaceutical; Health

21 Apr 2009
First Look

First Look: April 21, 2009

Industry Location Author:Arthur A. Daemmrich Abstract A consumer-oriented model for drug development and use has attracted attention in recent years as an alternative to the much-maligned approach of mass-marketing blockbuster drugs. In a... View Details

Keywords: Martha Lagace

15 Jul 2013
Research & Ideas

Five Imperatives for Improving Health Care

Innovation in health care treatment seems to far outpace innovation in health care business management. Just ask President Obama—two weeks ago he delayed enactment of a key provision of the new health care law for fear its requirements... View Details

Keywords: by Carmen Nobel; Health

2024
Article

Beyond the 510(k): The Regulation of Novel Moderate-Risk Medical Devices, Intellectual Property Considerations, and Innovation Incentives in the FDA’s De Novo Pathway

By: Mateo Aboy, Cristina Crespo and Ariel Stern

Moderate-risk medical devices constitute 99% of those that have been regulated by the U.S. Food and Drug Administration (FDA) since it gained authority to regulate medical technology nearly five decades ago. This article presents an analysis of the interaction between... View Details

Keywords: Governing Rules, Regulations, and Reforms; Health Care and Treatment; Technology Adoption; Technological Innovation; Safety; Medical Devices and Supplies Industry; United States